Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00408590 · ClinicalTrials.gov registry record · Phase 1
Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT00408590: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT00408590 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00408590, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
RATIONALE: A gene-modified virus may be able to kill tumor cells without damaging normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of an attenuated oncolytic measles virus therapy and oncolytic virus therapy in treating patients with progressive, recurrent, or refractory ovarian epithelial cancer or primary peritoneal cancer (measles virus vaccine therapy study closed as of 06/02/2008).
Interventions
- OTHER laboratory biomarker analysis
- GENETIC reverse transcriptase-polymerase chain reaction
- BIOLOGICAL carcinoembryonic antigen-expressing measles virus
- BIOLOGICAL oncolytic measles virus encoding thyroidal sodium iodide symporter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2004-04-19 |
| Est. Completion | 2017-11-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00408590
The ClinicalTrials.gov registry entry for NCT00408590 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00408590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00408590 about?
NCT00408590 is a clinical study titled "Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer". RATIONALE: A gene-modified virus may be able to kill tumor cells without damaging normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of an attenuated oncolytic measles virus therapy and oncolytic virus therapy in treating patients with progressive, recurrent, or re...
What is the current status of trial NCT00408590?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2004-04-19. Estimated completion is 2017-11-07.
What interventions are being tested in trial NCT00408590?
The interventions under investigation include: laboratory biomarker analysis (OTHER), reverse transcriptase-polymerase chain reaction (GENETIC), carcinoembryonic antigen-expressing measles virus (BIOLOGICAL), oncolytic measles virus encoding thyroidal sodium iodide symporter (BIOLOGICAL).
Who is sponsoring clinical trial NCT00408590?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.